Home > Healthcare > Pharmaceuticals > Finished Drug Form > Melanoma Drugs Market

Melanoma Drugs Market Share

Report ID: GMI8769
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Melanoma Drugs Market Share

The market is characterized by the presence of established players offering a range of medications, including immunotherapies and targeted therapy drugs for melanoma treatment. Key players compete on factors such as product efficacy, safety profile, pricing, distribution networks, and brand reputation. Continuous focus on innovation, strategic partnerships, and mergers and acquisitions are common strategies employed to gain a competitive edge in this dynamic and evolving market.

Melanoma Drugs Market Companies

Prominent players operating in the melanoma drugs industry are as mentioned below:

Abbott Laboratories
Amgen Inc.
AstraZeneca
Bayer AG
Bristol-Myers Squibb Company
F. Hoffman-La Roche Ltd.
Genentech, Inc
Merck & Co. Inc.
Mylan N.V.
Novartis AG

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Melanoma drugs industry size was valued at USD 3.6 billion in 2023 and is expected to record USD 7.5 billion by 2032, attributed to the increasing incidence of melanoma globally, particularly in regions with high levels of ultraviolet (UV) radiation exposure.

Immunotherapy drugs segment size reached USD 1.6 billion in 2023, due to their remarkable efficacy and relatively favorable safety profiles compared to traditional treatments.

Demand for branded melanoma drugs is expected to reach USD 6.9 billion by 2032, driven by their strong brand recognition, extensive marketing efforts, and perceived efficacy and safety profiles.

North America recorded 39.2% of the global melanoma drugs market share in 2023 and may reach USD 2.9 billion by 2032, due to the advanced healthcare infrastructure, high awareness levels regarding melanoma, and significant R&D investments in oncology.